Anacor Pharmaceuticals, Inc. 4
4 · Anacor Pharmaceuticals, Inc. · Filed Jun 24, 2016
Insider Transaction Report
Form 4
IPPOLITO VINCENT P
EVP & Chief Commercial Officer
Transactions
- Disposition to Issuer
Performance Restricted Stock Units
2016-06-24−5,000→ 0 total→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−28,400→ 0 totalExercise: $37.81→ Common Stock (28,400 underlying) - Disposition to Issuer
Performance Restricted Stock Units
2016-06-24−6,930→ 0 total→ Common Stock (6,930 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−61,000→ 0 totalExercise: $19.96→ Common Stock (61,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2016-06-24−25,299→ 0 totalExercise: $78.91→ Common Stock (25,299 underlying) - Disposition to Issuer
Common Stock
2016-06-24$99.25/sh−68,985$6,846,761→ 0 total
Footnotes (2)
- [F1]As of the effective time of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 14, 2016 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Quattro Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement, (i) each share of the Issuer's Common Stock held by the reporting person was disposed of in exchange for the merger consideration of $99.25 per share, (ii) each award of restricted stock units (including performance restricted stock units) and stock options became fully vested and (iii) each award of restricted stock units (including performance restricted stock units) and stock options was cancelled in exchange for the right to receive a cash payment per share in an amount equal to $99.25 less, in the case of stock options, the applicable exercise price.
- [F2]Includes shares acquired pursuant to the Issuer's ESPP since the reporting person's last Form 4.